50371-30-7

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Naphthalenedione, 2-(bromomethyl)is used as a key intermediate in the synthesis of naphthoquinone derivatives, which possess neoplasm inhibiting activity. These derivatives are valuable in the development of anticancer drugs, as they can target and inhibit the growth of cancerous cells, providing a potential therapeutic approach to cancer treatment.
Used in Chemical Synthesis:
In the chemical industry, 1,4-Naphthalenedione, 2-(bromomethyl)serves as a versatile building block for the creation of various naphthoquinone-based compounds. Its bromomethyl group allows for further functionalization and modification, enabling the synthesis of a wide range of naphthoquinone derivatives with diverse applications, such as dyes, pigments, and other specialty chemicals.

Upstream product

• 58-27-5 menadione 
• 939-26-4 2-bromomethylnaphthyl bromide 

Downstream Products

• 81402-12-2 2-(hydroxymethyl)-1,4-naphthoquinone N-methylcarbamate 
• 55700-10-2 2-(hydroxymethyl)naphthalene-1,4-dione 
• 81402-09-7 2-{[(p-toluenesulfonyl)oxy]methyl}-1,4-naphthoquinone 
• 39510-88-8 2-Methoxymethyl-1,4-naphthoquinone 

Relevant academic research and scientific papers

Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase

Pyruvate kinase M2 (PKM2) is a rate-limiting enzyme of the glycolytic pathway which is highly expressed in cancer cells. Cancer cells rely heavily on PKM2 for anabolic and energy requirements, and specific targeting of PKM2 therefore has potential as stra

Aminodithioformate compounds, preparation method therefor and use of aminodithioformate compounds in preparation of antitumor drugs

The invention discloses a series of aminodithioformate compounds, a preparation method therefor and use of aminodithioformate compounds in preparation of antitumor drugs. Through carrying out activity screening on a micromolecular compound library, a novel structure type of PKM2 inhibitors are discovered from the micromolecular compound library, and a series of aminodithioformate compounds with a structure represented by a general formula I shown in the description are designed and synthesized according to the inhibitors. Proven by enzyme activity tests, the compounds have remarkable superior PKM2 inhibiting activity and selectivity to those of currently available PKM2 inhibitors. Through separately carrying out killing effect test on pyruvate kinase M2 and M2 subtypes and four kinds of tumor cell lines, i.e., MCF-7, HCT116, Hela and H1299 by using the compounds disclosed by the invention, activity tests prove that the compounds have a remarkable tumor cell proliferation inhibiting action.

Synthetic approaches to 3-amino-1,4-naphthoquinone-2-carboxylic acid derivatives and photochemical synthesis of novel 1,4,5,10-tetrahydro-5,10- dioxo-2H-naphth[2,3-d][1,3]oxazine derivatives

Synthesis of 3-alkylamino-1,4-naphthoquinone-2-carboxylic acid (2) was attempted. Although 3-(1-piperidinyl)-1,4-naphthoquinone-2-carboxylic acid (2a) was not obtained, probably because of its instability, the esters (18a, b) of 2a could be prepared. 2-Alkylamino-3-hydroxymethyl-1,4-naphthoquinones (9a-g) were photochemically cyclized to the 1,4,5,10-tetrahydro-5,10-2H- napth[2,3-d][1,3]oxazines (19a-g), containing a novel heterocyclic ring system in moderate yields. Anti-bacterial activity of the prepared compounds was weak or insignificant.

2-and 6-methyl-1,4-naphthoquinone derivatives as potential bioreductive alkylating agents

A number of antineoplastic agents possess both the quinone nucleus and an appropriate substituent that permits them to function as bioreductive alkylating agents. To develop new compounds of this type with unique properties, the authors have synthesized a